Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after an interim ...
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the ...
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic ...
An NHS trust in the UK has become the first site in Europe to offer Roche's experimental drug trontinemab to patients ...
Like LDL-cholesterol, elevated Lp (a) is recognised as an independent genetic risk factor for coronary artery disease, heart ...
The EU Health Technology Assessment (HTA) Regulation became applicable on 12th January 2025, marking a fundamental shift in ...
There are currently two approved drugs in the oral SERD class, namely Menarini/Stemline's Orserdu (elacestrant) and Eli Lilly ...
London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575 million ($668 million), which will be used to "back Europe's boldest innovators." ...
Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...
Interim data from the 393-patient phase 3 CERVINO trial of etentamig (ABBV-383), a bispecific CD3 and BCMA-directed TCE, ...
The milestones in xenotransplantation – cross-species transplants – rely on cutting-edge biotechnologies, including the use ...
Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results